Myovant Sciences Ltd.
Healthcare · Pharmaceutical Preparations · CA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $231.0M | $59.3M | $0 | $0 | — | — |
| Operating income | −$187.3M | −$260.8M | −$274.9M | −$264.8M | −$143.0M | −$83.5M |
| Net income | −$206.0M | −$255.1M | −$289.0M | −$273.6M | −$143.3M | −$83.4M |
| Total assets | $520.0M | $725.0M | $105.9M | $173.0M | $119.1M | $185.3M |
| Total liabilities | $993.5M | $1.08B | $214.2M | $168.6M | $81.4M | $18.5M |
| Equity | −$473.5M | −$354.0M | −$108.3M | $4.3M | $37.7M | $166.8M |
| EPS (diluted) | $-2.22 | $-2.83 | $-3.37 | — | — | — |
| Shares out. | 95.3M | 91.5M | 89.9M | 72.2M | 64.9M | 60.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −81.1%
- Net margin
- −89.2%
- Return on equity
- 43.5%
- Return on assets
- −39.6%
- Return on capital (ROCE)
- −69.5%
- Liabilities / assets
- 191.1%
- Debt / equity
- —
- Book value / share
- $-4.97
- Revenue growth (YoY)
- 289.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -7.77distress
- Accruals / assets
- 12.0%high accruals
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Valente NancyDirector | Mar 10, 2023 | D | 3,673 | — |
| Potter Myrtle SDirector | Mar 10, 2023 | D | 3,673 | — |
| Merendino LaurenOfficer — Chief Commercial Officer | Mar 10, 2023 | D | 21,791 | — |
| Mehra UneekOfficer — Principal Financial Officer | Mar 10, 2023 | D | 20,724 | — |
| Marek David COfficer — Principal Executive Officer | Mar 10, 2023 | D | 95,675 | — |
| Lang MatthewOfficer — General Counsel & Corp. Secy. | Mar 10, 2023 | D | 113,145 | — |
| Gulfo Adele M.Director | Mar 10, 2023 | D | 3,673 | — |
| Guinan MarkDirector | Mar 10, 2023 | D | 3,673 | — |
| Curran TerrieDirector | Mar 10, 2023 | D | 3,673 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventMar 10, 2023
- Shareholder voteMar 1, 2023
- Results of operationsJan 26, 2023
- Results of operationsOct 26, 2022
- Entered a material agreement · Other material eventOct 24, 2022
- Shareholder voteOct 21, 2022
- Other material eventOct 3, 2022
- Results of operationsJul 27, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GMar 20, 2023
- EFFECTMar 16, 2023
- EFFECTMar 16, 2023
- 25-NSEMar 10, 2023
- 4FORM 4 SUBMISSIONMar 10, 2023
- 4FORM 4 SUBMISSIONMar 10, 2023
- 4FORM 4 SUBMISSIONMar 10, 2023
- 4FORM 4 SUBMISSIONMar 10, 2023
- S-8 POSMar 10, 2023
- S-8 POSMar 10, 2023
- S-8 POSMar 10, 2023
- S-8 POSMar 10, 2023
- S-8 POSMar 10, 2023
- S-8 POSMar 10, 2023
- S-8 POSMar 10, 2023
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.